Medikamentenvergleiche
Saxagliptin vs. Pioglitazone
Saxagliptin vs. Pioglitazon: DPP-4-Hemmer vs. TZD bei Typ-2-Diabetes. Vergleich der Herzinsuffizienzrisiken, Gewichtszunahme, Ödeme, Insulinresistenz und Nebenwirkungen.
Für diese Seite sind keine Vergleichsdimensionen verfügbar.
Klinischer Kontext
This comparison is triggered when type 2 diabetes patients on metformin require add-on oral therapy and must balance DPP-4 incretin effects against TZD insulin-sensitizing benefits amid cardiovascular and fluid-retention concerns.
Fazit
Saxagliptin generally suits patients prioritizing weight neutrality and lower edema risk, while Pioglitazone may be considered for significant insulin resistance, with neither inherently superior and selection based on individual risk profiles.
Alle Medikamentenvergleiche